Research is repeatedly showing that co-administration of individual drugs as combination therapy offers significant benefits to patients.
This trend of combining drugs is likely to increase in the near future, with combinations showing efficacy in complex diseases including cancer, HIV, rheumatoid arthritis and hepatitis C, among others.
But in Belgium, the existing reimbursement procedure faces difficulties when evaluating combination therapies. It was designed for individual medicines, from one company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze